Syntax Bio
Syntax Bio's discovery platform overcomes the longstanding challenges in stem cell-derived therapies by directly controlling and accelerating cell differentiation.
Healthcare & Biotech
Vision
Syntax Bio is a biotechnology company developing a CRISPR-based platform to accelerate and control the differentiation of induced pluripotent stem cells (iPSCs) into therapeutic-grade cells. Their proprietary "Cellgorithm" technology employs a modified CRISPR system to regulate gene expression in a precise, stepwise manner, mimicking natural developmental processes. This approach aims to overcome limitations of traditional methods by reducing differentiation timelines from months to days, enhancing scalability, and lowering manufacturing costs. Syntax Bio collaborates with biopharmaceutical companies, offering its platform to improve the efficiency and accessibility of cell therapy manufacturing.
Sub-Industries
Stem Cell Therapy
Regenerative Medicine
Cell Differentiation Technology
Testimonial
Related Companies
KindBio
The future of organ replacement
Salem, NH, USA
The Embryo Corporation
Scalable embryo gene editing to build the next generation of animal life
Austin, TX, USA
Paterna Biosciecnes
In vitro gematogenesis platform company to address male and female intertility
Salt Lake City, UT, USA
Proton Intelligence
Real-time wearable potassium monitoring
Vancouver, Canada
Origenity
AI-driven cell design, from next-generation genetic medicines to expanding what life can be
San Francisco, USA
Deep Root Biolabs
Plant-powered synthetic biology turning polluted soil into clean ground and reclaimed critical minerals
Baltimore, MD, USA
LightHearted AI
Revolutionizing Point-of-Care Cardiac Detection Using Photonics and AI
London, UK
